Success Metrics

Active Trials
1(25%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Enrolling by invitation2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

enrolling_by_invitation250%
withdrawn125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
enrolling_by_invitationphase_1

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

NCT06763965
recruitingphase_1

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

NCT07264569
withdrawnphase_1

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

NCT07150767
enrolling_by_invitationphase_1

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

NCT06215846

Clinical Trials (4)

Showing 4 of 4 trials
NCT06763965Phase 1

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Enrolling By Invitation
NCT07264569Phase 1

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

Recruiting
NCT07150767Phase 1

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

Withdrawn
NCT06215846Phase 1

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Enrolling By Invitation

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4